A preliminary study of a 68Ga-labeled PET probe for HER2 imaging

Abstract

Human epidermal growth factor receptor 2 (HER2) has emerged as an important molecular target for tumor diagnosis and therapy. The H6F peptide (YLFFVFER) selectively binds to the HER2 receptor. In this study, the H6F peptide was modified with glycine to improve water solubility and then linked to 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) for gallium-68 (⁶⁸Ga) labeling. The precursor was labelled with ⁶⁸Ga to generate ⁶⁸Ga-DOTA-GGG-H6F, and its stability and HER2 specificity were preliminarily assessed in vitro. Positron emission tomography (PET) imaging and biodistribution in human ovarian cancer SKOV-3 (HER2+) xenograft models revealed a high uptake of ⁶⁸Ga-DOTA-GGG-H6F in SKOV-3 tumors. The uptake of ⁶⁸Ga-DOTA-GGG-H6F in SKOV-3 tumors could be blocked by an excess of the H6F peptide. Furthermore, the uptake of ⁶⁸Ga-DOTA-GGG-H6F in human breast cancer MDA-MB-231 (HER2−) tumors was low. HER2 expression was confirmed by immunohistochemistry and immunofluorescence staining. Autoradiography and pathological staining revealed a high correlation between radioactivity distribution and HER2 expression in tumors. These results confirmed the specificity of ⁶⁸Ga-DOTA-GGG-H6F to HER2. In conclusion, we successfully developed a novel HER2-targeted PET imaging probe that exhibited significant potential for the detection of HER2 expression in tumors.